Key statistics
As of last trade, Climb Bio Inc (CLYM:NMQ) traded at 3.05, 29.94% above the 52 week low of 2.35 set on Dec 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.03 |
---|---|
High | 3.30 |
Low | 3.03 |
Bid | 3.05 |
Offer | 3.06 |
Previous close | 3.00 |
Average volume | 277.95k |
---|---|
Shares outstanding | 67.06m |
Free float | 60.10m |
P/E (TTM) | -- |
Market cap | 201.18m USD |
EPS (TTM) | -2.13 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:27 GMT.
More ▼
- Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
- Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
- Climb Bio to Present at Upcoming Investor Conferences
- Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
- Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
- Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
- Climb Bio to Host Virtual Investor Event on October 15, 2024
- Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
- Eliem Therapeutics Announces Additions to its Leadership Team
More ▼